`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`RESEARCH CORPORATION TECHNOLOGIES, INC.,
`Patent Owner.
`
`Case No. IPR2016—01248
`
`Patent No. RE38,551
`
`
`
`PATENT OWNER RESEARCH CORPORATION TECHNOLOGIES,
`INC.’S MANDATORY NOTICES UNDER 37 C.F.R. § 42.8
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016—01248
`
`Pursuant
`
`to 37 C_.F.R.
`
`§ 42.8, Patent Owner Research Corporation
`
`Technologies, Inc. submits the following Mandatory Notices. In accordance with
`
`37 C.F.R. 42.8(a)(2), these Mandatory Notices are being timely filed within 21
`
`days of service of the petition.
`
`A.
`
`Real Party-In-Interest Under 37 C.F.R. § 42.8(b)(1)
`
`The real parties—in-interest are Research Corporation Technologies, Inc.;
`
`Harris FRC Corporation; UCB, Inc.; UCB Biopharma SPRL; and UCB Pharma
`
`GmbH.
`
`B.
`
`Related Matters Under 37 C.F.R. § 42.8(b)(2)
`
`The Patent Trial and Appeal Board denied an earlier filed Petition for Inter
`
`Partes Review of RE38,551, IPR2014—01126. A second Petition for Inter Partes
`
`Review of RE38,551, IPR2016-00204, was filed on November 23, 2015, and was
`
`instituted on May 23, 2016. Three further Petitions for Inter Partes Review of
`
`RE38,551 have been filed: IPR2016-01101, May 25, 2016; IPR2016—01242, June
`
`21, 2016;
`
`and IPR2016~01245,
`
`June 22, 2016. A request
`
`for ex parte
`
`reexamination of RE38,551 (Control No. 90/013,709) was filed on March 25,
`
`2016, and granted on June 16, 2016.
`
`Patent Owner further identifies the following related judicial proceedings
`
`involving RE38,551:
`
`
`
`Patent No. RE38,551
`
`Case No. lPR2016—Ol248
`
`Case Caption
`UCB, Inc. et al. v. Teva Pharmaceuticals USA Inc.
`et al., 1:13—cV—O1148—LPS (D. De1_.)
`UCB, Inc. et al. v. Accord Healthcare Inc. et al.,
`1:13-cv—01206—LPS (D. Del.)
`UCB, Inc. et al. v. Alembic Pharmaceuticals Ltd.,
`1:13—cv~01207—LPS (D. Del.)
`UCB, Inc. et al. v. Amneal Pharmaceuticals, LLC
`et al., 1:13-cv—O1208—LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:13-cV—
`01209-LPS (D. Del.)
`UCB, Inc. et al. v. Aurobindo Pharma Ltd. et al.,
`
`Disposition
`closed
`
`pending
`
`
`
`pending, Consolidated with
`1:13—cV—01206-LPS (D. Del.)
`pending, Consolidated with
`1:13—cV-012O6—LPS (D. Del.)
`pending, consolidated with
`1:13-cV—O1206—LPS (D. Del.)
`pending, consolidated with
`
`1:13—cv—01210—LPS (D. Del.)
`
`) 1:13—CV—01206~LPS (D. Del:)
`
`pending, consolidated with
`1:13-cv—01206—LPS (D. Del.)
`closed
`
`UCB, Inc. et al. V. Breckenridge Pharmaceutical
`Inc. et al., 1:13—CV—O1211—LPS (D. Del.)
`UCB, Inc. et al. v. Glenmark Generics Inc. USA et
`al., 1:13—CV—01212—LPS (D. Del.)
`UCB, Inc. et al. v. Hetero USA Inc. et al., 1:13—cV— Closed
`O1213~LPS (D. Del.)
`UCB, Inc. et al. v. Mylan Pharmaceuticals Inc. et
`al., 1:13—CV—O1214—LPS (D. Del.)
`UCB, Inc. et al. v. Ranbaxy Laboratories Ltd. et
`al., 1:13-CV-01215—LPS (_D. Del.)
`UCB, Inc. et al. v. Sandoz Inc., 1:13—cv-01216—
`LPS (D. Del.)
`UCB, Inc. et al. v ScieGen Pharmaceuticals Inc. et Closed
`al., 1:13—CV—01217—LPS (D. Del.)
`UCB, Inc. et al. 12 Sun Pharma Global FZE et al.,
`1:13—cv~O1218—LPS (D. Del.)
`UCB, Inc. et al. v. Watson Laboratories Inc. —
`Florida et al., 1:13—CV—01219—LPS (D. Del.)
`UCB, Inc. et al. v. Zydus Pharmaceuticals (USA)
`Inc. et al., 1:13-cV—0122()-LPS (D. Del.)
`UCB, Inc. et al. v. Apotex Corp. et al., 1:14—cv—
`O0834—LPS (D.De1)
`
`pending, consolidated with
`1:13-CV—01206-LPS (D. Del.)
`Closed
`
`closed
`
`1
`
`1
`
`pending, Consolidated with
`1:13-cv-01206-LPS (D. Del.L
`pending, consolidated with
`1:l3—cV—01206—LPS (D. Del.)
`pending, consolidated with
`1:13-cv-01206-LPS (D. Del.)
`l pending, consolidated with
`1:13-CV~—01206-LPS (D. Del.)
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016-01248
`
`Case Caption
`UCB, Inc. et al. v. Sun Pharma Global FZE et al.,
`’l:l3—cv-05514 QED. Ill)
`UCB, Inc. et al., v. Zydus Pharmaceuticals (USA),
`Inc. et al., 3:13—cV-04021 (D.N.J.)
`
`' Disposition
`closed
`
`closed
`
`C.
`
`Lead and Back-Up Counsel Under 37 C.F.R. § 42.8(b)(3)
`
`T
`Back-Up Counsel
`Lead Counsel
`ienniier L‘ R°bbi“S (Reg NO‘ 61463)
`Andrea G. Reister (Reg. No. 36 253)
`Jl’r(());)t12)1in:r§‘§Clr(l):1]n(il(i1D1e1ivery Address‘
`areiSter@C0V'COm
`Covington & Burling LLP
`'
`Postal and Hand—Deliver Address:
`.
`.
`.
`Covington & Burling LLP
`One CityCenter 850 Tenth Street NW The New York Tunes Building
`’
`’
`620 Eighth Avenue
`Washington, DC 20001
`New York, NY 10018
`Telephone: (202) 662-5141
`Telephone: (212) 841-1180
`Facsimile: (202) 778-5141
`Facsimile: (212) 841-1010
`
`Additional Back-Up Counsel
`Enrique D. Longton (Reg. No. 47,304)
`rlongton@coV.com
`Postal and Hand-Delivery Address:
`Covington & Burling LLP
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`Telephone: (202) 662-5108
`Facsimile: (202) 778-5108
`
`D.
`
`Service Information Under 37 C.F.R. § 42.8(b) (4)
`
`Service information for
`
`lead and back-up counsel
`
`is provided in the
`
`designation of lead and back-up counsel, above. Service of any documents via
`
`hand-delivery may be made at the postal mailing address of the respective lead and
`
`
`
`Patent No. RE38,551
`
`Case No. IPR2016-01248
`
`back—up
`
`counsel designated above.
`
`Patent Owner Reseach Corporation
`
`Technologies, Inc. consents to electronic service by email at the above listed email
`
`addresses of lead and back—up counsel.
`
`E.
`
`Power of Attorney
`
`The above-designated counsel at Covington & Burling LLP are currently
`
`counsel of record for RE38,551, thus no additional Power of Attorney is submitted
`
`herewith.
`
`Date: July 12, 2016
`
`Respectfully submitted,
`
`
`
`Andrea G. Reister
`Registration No. 36,253
`Jennifer L. Robbins
`
`Registration No. 61,163
`COVINGTON & BURLING LLP
`
`One CityCenter, 850 Tenth Street, NW
`Washington, DC 20001
`(202) 662-6000
`Attorneys for Patent Owner
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6, I hereby certify that on this 12th day of July 2016,
`
`the foregoing Patent Owner Research Corporation Technologies, lnc.’s Mandatory
`
`Notices Under 37 C.F.R. § 42.8 was served by FedEX®, a means at least as fast and
`
`reliable as Priority Mail EXpI‘€SS®,
`
`on the following counsel of record for
`
`petitioner.
`
`Steven W. Parmelee (sparrne1ee@wsgr.com)
`Michael T. Rosato (mrosato@wsgr.com)
`Jad A. Mills (jmills@wsgr.com)
`Wilson Sonsini Goodrich & Rosati
`
`701 Fifth Avenue, Suite 5100
`
`Seattle, WA 98104
`
`Date: July 12, 2016
`
`/3
`2
`/i,/
`x’1»"}‘”:/efie
`fr» *5
`/
`
`
`Andrea G. Reis er, Esq.
`Registration No.: 36,253
`
`,1